NCT05626257View on ClinicalTrials.gov

Regulatory Post-Marketing Surveillance of Xolair® for Chronic Rhinosinusitis With Nasal Polyps

CompletedOBSERVATIONAL
Enrollment

135

Participants

Timeline

Start Date

January 12, 2023

Primary Completion Date

April 15, 2025

Study Completion Date

April 15, 2025

Conditions
Chronic Rhinosinusitis With Nasal Polyps
Interventions
OTHER

Xolair

There is no treatment allocation. Patients administered Xolair by prescription that have started before inclusion of the patient into the study will be enrolled.

Trial Locations (12)

11759

Novartis Investigative Site, Uijeongbu-si

13620

Novartis Investigative Site, Bundang Gu

14068

Novartis Investigative Site, Anyang-si

16247

Novartis Investigative Site, Suwon

03312

Novartis Investigative Site, Seoul

08308

Novartis Investigative Site, Seoul

705 718

Novartis Investigative Site, Daegu

405 760

Novartis Investigative Site, Incheon

03080

Novartis Investigative Site, Seoul

03722

Novartis Investigative Site, Seoul

06351

Novartis Investigative Site, Seoul

07061

Novartis Investigative Site, Seoul

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY